



Agenzia Italiana del Farmaco



Case Study of Fraud An Italian Experience and Following Actions

Fabrizio Galliccia GCP Senior Inspector

The Beginning



- BE Application
- 2 studies
- During the assessment, some doubts were raised
- An Inspection was requested by the AIFA Office for Marketing Authorization



The 1st Inspection



- The inspection was announced just one week before, without mentioning the studies
- 5 days inspection





The 1st Inspection: Critical Findings



- Analysis of unknown samples were backdated (to 1 year back)
- Long Term Stability was not performed
- HPLC software without audit trail system
- Lack of source documents / lack of traceability (weighing of standards, stock solution preparation, preparation of calibration samples and QC samples...logbook...)
- Lack of temperature logs
- Lack of freezer logs









The 1st Inspection: Outcome

- Analysis backdated = Public Prosecutor
- MA = not granted
- Warning on the Lab!!!!
 - 1. Problems about other studies performed by the Lab (2004 2009)
 - 2. Problems about future studies







Activities of the Lab have been stopped until suitable corrective actions would be implemented







The Italian Inspectorate was requested to inspect all studies of this Lab related to MA (granted or submitted)







The Italian Inspectorate was requested to inspect all studies of this Lab related to MA (granted or

submitted)





Type of Inspections



- Study Specific Inspection: strong results but time consuming...
- System Inspection: it is difficult to check system in the past; it is difficult to apply the results of system inspection on single studies in order to take regulatory decisions...





Inspection on Key (strong) Points – System inspection on specific studies

Key point to verify	Study xxx	Study yyy	Study zzz			
Analysis backdated						
Monitoring on lab activities						
Audit on lab activities						
Software audit Trail						
Compliance with Guideline FDA on Method Validation						
Source documents on validation			Ft			
Source documents on unknown samples						
Long term stability demonstrated						
Temperature records & Freezer Logs						
Authorised manufacturer of IMP						
E-records of chromatograms						
12 11-14 October 2009						

Inspection on Key (strong) Points – System inspection on specific studies

Key point to verify	Study xxx	Study yyy	Study zzz
Analysis backdated	NO	NO	NO
Monitoring on lab activities	NO	NO	NO
Audit on lab activities	NO	NO	NO
Software audit Trail	NO	NO	NO
Compliance with Guideline FDA on Method Validation	NO	YES	YES
Source documents on validation	NO	Incomplete	YES
Source documents on unknown samples	NO	Incomplete	YES
Long term stability demonstrated	NO	YES	YES
Temperature records & Freezer Logs	NO	Incomplete	YES
Authorised manufacturer of IMP	NO	YES	YES
E-records of chromatograms	NO	YES	YES



Inspection on Key (strong) Points – System inspection on specific studies

• <u>Strong Points</u>



- Many studies could be inspected in a short time
- Inspection conclusions can be used for regulatory decisions
- Weak Points
 - It works just in case of glaring critical findings
 - It allows to distinguish just situations like YES/NO
 - In case of uncertain feedback, a study specific inspection is required





THANK YOU

